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Metalloproteinasesa b s t r a c t
Peyronie’s disease is characterized by fibrous plaque formation of the tunica albuginea, causing penile
deformity and fertility problems. The aim of the present study was to investigate alterations in the extra-
cellular matrix in Peyronie’s disease. The study used tissues collected by surgical procedure from individ-
uals that presented a well-established disease, while control samples were obtained by biopsies of fresh
cadavers. Immunohistochemistry analysis followed by digital quantification was performed to evaluate
TGF-b, heparanases and metalloproteinases (MMPs). The profile of sulfated glycosaminoglycans, chon-
droitin sulfate and dermatan sulfate was determined by agarose gel electrophoresis, while hyaluronic
acid quantification was obtained by an ELISA-like assay. The expression of mRNA was investigated for
syndecan-1 proteoglycan (Syn-1), interleukine-6 (IL-6), hyaluronic acid synthases, and hyaluronidases.
Pathologic features showed decreased apoptosis and blood vessel number in Peyronie’s tissues. TGF-b
and IL-6 were significantly enhanced in Peyronie’s disease. There was an increased expression of hep-
aranases, though no alteration was observed for MMPs. Hyaluronic acid as well as hyaluronic acid syn-
thases, hyaluronidases, and dermatan sulfate were not changed, while the level of chondroitin sulfateper.
456 M.S. Watanabe et al. / Journal of Advanced Research 8 (2017) 455–461was significantly (P = 0.008, Mann-Whitney test) increased in Peyronie’s samples. Heparanases and sul-
fated glycosaminoglycans seem to be involved in extracellular matrix alterations in Peyronie’s disease.
 2017 Production and hosting by Elsevier B.V. on behalf of Cairo University. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Peyronie’s Disease (PD) was first described in 1743 [1], but is
still poorly understood. It affects between 0.4% and 9% of men
and has a highly adverse impact on the quality of life of patients
and partners, because of the impairment of sexual performance
and accompanying low self-esteem [2]. Ok PD’s pathophysiology
is not completely understood. Apparently, there is a disturbance
of the healing mechanism of the tunica albuginea, which can be
damaged by micro-traumas during sexual intercourse [3]. This dis-
order leads to the formation of a fibrous plaque, which results in a
non-distensible area of tunica albuginea, which causes penile
deformity during erection. Accumulating evidence suggests that
the overexpression of transforming growth factor-b (TGF-b1) may
be associated with the pathogenesis of PD [4].
Dupuytren’s disease is a palmar fibromatosis leading to pro-
gressive digital flexion contracture [5] and appears to have the
same physiopathology as PD. Several studies related to Dupuytren
describe alterations in the extracellular matrix, an increased
TGF- which affects the expression of major extracellular matrix
(ECM) proteins, fibronectin, and collagen [5,6]. Thus, it is important
to understand the possible alterations of ECM in patients with PD
to clarify the pathogenesis of the disease.
Our aim was therefore to investigate the alterations in the
extracellular matrix in Peyronie’s disease in an effort to elucidate
the molecular mechanisms involved in the development of the dis-
ease. Key molecules could be useful as potential targets for future
therapies and thus benefit the treatment of patients.Subject and methods
Patients and samples
The study was composed of tissues collected from individuals
unaffected by Peyronie’s disease, control group (N = 7) and samples
from Peyronie’s patients (N = 10). The Peyronie’s patients included
in this study had already been recommended for surgery and pre-
sented a well-established disease. Tissue samples in the control
group were obtained from fresh cadavers. During the resection,
samples of 1 cm were collected from the tunica albuginea of unaf-
fected individuals and patients with Peyronie’s disease. The sam-
ples were divided into three fragments, one fragment was stored
in acetone for biochemical analysis (glycosaminoglycan quantifica-
tion), the second fragment was stored in 10% buffered formalin for
immunohistochemistry assays, and the third sample was stored in
RNA Holder and used for molecular biology studies (mRNA expres-
sion analysis). The study was approved by the Human Ethics Research
Committee at Faculdade de Medicine do ABC (No. 242/2010).Pathological analysis
Tissue samples of albuginea (3 mm thick) previously fixed in for-
malin and incubated in paraffin were deparaffinized and rehy-
drated. Two staining were made: Hematoxylin - Eosin (HE) and
Masson Trichome. Under the HE staining, microvessels, cells, and
apoptotic events were evaluated. Under Masson Trichrome stain-
ing, fibrosis was assessed. This evaluation produced a semi-
quantitative score: absent (zero); mild (+); moderate (++); andintense (+++). Each sample was evaluated by three different
pathologists.
Immunohistochemistry assay
The slices were incubated overnight at 4 C with the primary
antibodies anti-TGF-b, anti-heparanase-1, anti-heparanase-2,
anti-MMP-2 and anti-MMP-9 (Santa Cruz Biotechnology, CA,
USA). Finally, the slides were incubated with a biotin-avidin-
peroxidase complex and developed using 3,30-diaminobenzidine
as the chromogen (LSAB, Dako Cytomation, Glostrup, Denmark)
for 30 min. The slides were examined under a light microscope
(Nikon Eclipse TS100). Two independent observers scored 300
cells according to the presence of staining for each of the antibod-
ies as mentioned above. The immunocytochemistry staining was
analyzed by digital quantification following the methodology
described by Matos et al. [7]. The values were expressed as optical
units per square micrometer (ou/mm2).
Real-time PCR
Quantitative Real-Time PCR (qPCR) was used to evaluate mRNA
expression of interleukine-6 (IL-6), heparan sulfate proteoglycan
syndecan-1 (Syn-1), hyaluronic acid synthases (HAS1, HAS2, and
HAS3) and hyaluronidases (Hyl1 and Hyl2). Total tissue RNA was
extracted using Trizol reagent (Life Technologies, CA, USA), accord-
ing to manufacturer’s instructions. cDNA samples were obtained
with 1 mg of pure RNA for the reverse transcriptase PCR (RT-PCR),
using the ImProm-IITM Reverse Transcription System (Promega,
CA, USA) according to manufacturer’s instructions. qPCR was per-
formed according to manufacturer’s instructions using 1 mg of
cDNA and SYBR Green Master Mix (Life Technologies, CA, USA).
The normalization of the expression of the target genes was
determined using the geometric mean of the two endogenous
genes glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and
b-actin, and the values of expression were corrected using 2DCt.
Analysis of sulfated glycosaminoglycans
The tissues were homogenized in acetone, centrifuged for
15 min (3000g) and dried at 60 C. The homogenized tissue was
submitted to proteolysis with Alcalase (Novozyme) diluted
100 times. The proteolysis was carried out at 50 C overnight,
followed by trichloroacetic acid precipitation (TCA 90% in the
presence of 5 M NaCl), to remove protein debris. The precipitation
of sulfated glycosaminoglycans was performed using two volumes
of methanol, at 20 C, overnight. An aliquot of 5 mL of each
sample was subjected to agarose gel electrophoresis, using 1,3-
diaminopropane-acetate 0.05 M, pH 9.0. After electrophoresis and
precipitation of sulfated glycosaminoglycans using cetyltrimethy-
lammonium 0.1%, the gel was dried and stained with toluidine blue
for identification and quantification of each glycosaminoglycan by
densitometry using Epson Perfection V700 Photo equipment.
Hyaluronic acid quantification
The ELISA-like assay was performed for hyaluronic acid quan-
tification as described by Martins and his co-authors [8]. A 96-
well plate was coated with hyaluronic acid binding protein (link
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jugated link protein to biotin and europium labeled streptavidin.
Subsequently, the samples containing hyaluronic acid were added
promoting a dislodgement of standard linked hyaluronic acid,
releasing consequently, europium in solution. The final fluores-
cence was quantified in a fluorometer, and the amount of fluores-
cence was directly proportional to the amount of hyaluronic acid in
each sample.
Statistical analysis
The expression of mRNA and protein were determined by mean
and standard deviation using nonparametric and unpaired tests.
The glycosaminoglycans quantification was described by the med-Table 1
Pathological Features from control and Peyronie’s samples.
Patients Total Cells Fibrocytes Other cells Blood
AFM 53 13 40 10
ARC 27 8 18 Zero
DESC 28 4 27 2
ISS 57 16 39 4
LSF 91 15 82 4
M C O 109 35 79 12
Average 61 16 48 5
JAA 42 9 37 2
BCL 45 18 27 Zero
JLV 41 13 19 Zero
SMP 69 28 40 6
JPN 94 17 61 Zero
JRCM 68 19 54 8
PAOS 52 18 34 4
Average 59 17.4 39 2.5
Each individual was indicated with initial letters of the name. The values expressed repr
obtained after the analysis of each sample by three different pathologists. The extracellul
as mild (+), moderate (++) or intense (+++) labelling. Control, tissues collected from non-a
Fig. 1. Immunohistochemistry quantification of transforming growth fator-b (TGF-b). A
The dots (circles and squares) represent the values obtained by digital quantification
unaffected individuals. The number of samples used was described in methods (N = 10 an
of TGF-b expression in each group (P* = 0.0011; Nonparametric unpaired test).ian and Mann-Whitney test was used for comparison between two
groups. For all analysis, a statistical significance level of 5% was
adopted (P < 0.05), and Prism software version 5.0 (GraphPad
Prism Software Inc, California, USA) was used.
Results
Pathological features
Histological analysis of penile tissue obtained from the control
group and patients with Peyronie’s disease demonstrated
decreased number of blood vessels and apoptosis in Peyronie’s
tissues (Table 1). However, no differences were detected in the
number of cells, nerves or fibers.Vassels Nerves Fibers Apoptosis















esent the number of cells, vessels and apoptotic events. The average numbers were
ar matrix fibers were determined by hematoxylin eosin staining and was quantified
ffected individuals; Peyronie, tissues obtained from patients with Peyronie disease.
, Immunohistochemistry reaction obtained from control and Peyronie’s samples. B,
of immunohistochemistry reactions from each tissue of Peyronie’s patients and
d N = 7), for control and Peyronie’s group, respectively. The lines indicate mean value
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The assessment by immunohistochemistry analysis and digital
quantification evidenced a significant increase in TGF-b expression
in the Peyronie’s samples (83.0 ou/mm2) compared to control group
(122.0 ou/mm2 as shown in Fig. 1. The mRNA expression of
interleukin-6 was higher in the tissues of Peyronie’s patients than
in the control group (Fig. 2). Increased levels of TGF-b is the major
feature that determines the presence of Peyronie’s disease. The rel-Fig. 2. Interleukin-6 (IL-6) expression. The IL-6 mRNA expression was determined
by quantitative RT-PCR analysis as described in Methods. The normalization of the
expression of the target genes was determined using the geometric mean of the two
endogenous genes glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and b-
actin, and the values of expression were corrected using 2DCt. The number of
samples used was described in methods (N = 10 and N = 7), for control and
Peyronie’s group, respectively. Control, unaffected group; Peyronie’s, patients
affected by Peyronie’s disease. The result was expressed as mean and standard
deviation. Nonparametric unpaired test, P* = 0.0104.
Fig. 3. Metalloprotease analysis. Panels A, Immunohistochemistry reactions were used to
Panels B, the dots indicate the values obtained by digital quantification of MMP2 and MM
group. The number of samples used was described in methods (N = 10 and N = 7), for c
expression. P values were obtained using Nonparametric unpaired test.ative expression of IL-6 was higher in Peyronie’s than in the control
group, 4.86 ou/mm2 and 0.076 ou/mm2, respectively (Fig. 2).
To check for extracellular remodeling, we investigated some
metalloproteases and glycosidases involved in such mechanism.
There were no changes in the immunohistochemistry expression
of metalloproteinase-2 (MMP2) and metalloproteinase-9 (MMP9)
in Peyronie’s and control group (Fig. 3). The mean of MMP2 expres-
sion was not altered; 85.95 ou/mm2 and 93.04 ou/mm2; for control
and Peyronie’s group, respectively (Fig. 3). There was also no differ-
ence between MMP9 expression in control (112.28 ou/mm2) and
Peyronie’s group (119.71 ou/mm2) as shown in Fig. 3. However,
there was a significant difference in heparanase-1 and
heparanase-2 expression. Both heparanases were significantly
increased in the Peyronie’s group compared to the control group
(151.48 ou/mm2 and 130.8 ou/mm2) and (107.17 ou/mm2 and
113.60 ou/mm2), respectively (Fig. 4). The expression of heparan
sulfate proteoglycan mRNA, syndecan-1 (Syn-1), was not altered,
as shown in Fig. 5.Glycosaminoglycan investigation
Fig. 6 shows that sulfated glycosaminoglycans, chondroitin sul-
fate (CS) was significantly increased in the tissues of patients
affected by Peyronie’s disease, compared to the control group,
while no difference was observed for dermatan sulfate and non-
sulfated glycosaminoglycan hyaluronic acid (HA). The median for
CS was 5.49 mg/mg tissue in the control vs. 11.78 mg/mg tissue in
Peyronie’s group (P = 0.008). Dermatan sulfate was not altered in
patients with Peyronie (43.13 mg/mg tissue) compared to control
group (23.39 mg/mg tissue). On the other hand, there was no differ-
ence between the median values of HA in control (0.67 mg/mg of
tissue) as well as Peyronie’s (0.29 mg/mg tissue) group. No differ-
ence was observed in the expression of hyaluronic acid synthases
(HAS1 and HAS2) and hyaluronidases (Hyl1 and Hyl2), when theinvestigate Metalloprotease-2 (MMP2) and metalloprotease-9 (MMP9) expression.
P9 determined in the tissue of each control (unaffected individuals) and Peyronie’s
ontrol and Peyronie’s group, respectively. The lines represent mean value of MMPs
Fig. 4. Expression of heparanase isoforms. Heparanase-1 and heparanase-2 were investigated by immunohistochemistry reactions (Panels A), while the expression values
were determined by digital quantification (Panels B). The number of samples used was described in methods (N = 10 and N = 7), for control and Peyronie’s group, respectively.
Each dot of the Scatchard plot specifies one sample obtained from control (unaffected individuals) and patients with Peyronie’s disease, indicated by circles and squares,
respectively. Both P values were obtained by Nonparametric unpaired test, P* = 0.0004 and P* = 0.0250, for control and Peyronie group, respectively.
Fig. 5. Quantitative expression of syndecan-1. Quantitative RT-PCR was used to
determine the expression of mRNA of syndecan-1, as previously described in
Methods. The number of samples used was described in methods (N = 10 and N = 7),
for control and Peyronie’s group, respectively. The normalization of the expression
of the target genes was determined using the geometric mean of the two
endogenous genes glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and b-
actin. The values represent mean and standard deviation of syndecan-1 expression
determined by 2DCt.
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lyzed, as shown in Fig. 7. As well, there was a non-significant
expression of mRNA hyaluronic acid synthase-3 (HAS3), in both
the Peyronie’s and control group, suggesting that HAS3 is not
expressed in the albuginea tunica (data not shown).Discussion
A decreased number of blood vessels in Peyronie’s samples
compared to control samples indicated a less intense process ofangiogenesis. Apoptosis was also reduced in the Peyronie’s tissue
samples. There were no differences in the number of cells, nerves
or fibers comparing Peyronie’s patients and non-affected tissues,
possibly because the disease might be at a stage where such alter-
ations were not expressive.
Increased levels of TGF-b proved the presence of Peyronie’s dis-
ease in the analyzed samples of the patients investigated in the
present study. A direct correlation was found between TGF-b level
and the development and the severity of Peyronie’s disease [4]. The
increased level in IL-6 corroborates with the enhancement of TGF-b
since both molecules are involved in the inflammatory process that
occurs in Peyronie’s disease.
Extracellular matrix remodeling involves the action of different
enzymes. In the present study, heparanase-1 (HPSE) expression
was significantly enhanced, while no difference was observed for
metalloproteases (MMP2 and MMP9). These combined results
indicate that, in Peyronie’s disease, the glycosidase HPSE, which
is involved in the degradation of heparan sulfate chains from pro-
teoglycans, has a more pronounced role than metalloprotease
activity in extracellular matrix remodeling. It is well known that
oligosaccharides generated by the action of heparanase-1 can
intensify the action of growth factors, cytokines, angiogenic and
inflammatory factors [9].
The function of heparanase-2 (HPSE2) remains unknown.
Some authors have described an increased expression of HPSE2
in tumor tissues [10,11]. HPSE2 can also modulate the catalytic
activity of HPSE [12,13]. Therefore, HPSE2 might be involved in
the regulation of heparanase-1 in Peyronie’s disease. It is impor-
tant to point out that increased expression of HPSE and HPSE2 is
an entirely new result in the literature and such data open the
possibility of further studies on this topic and may contribute
to elucidate molecular mechanisms involved in the alterations
in Peyronie’s disease.
Fig. 6. Profile of glycosaminoglycans. A, chondroitin sulfate (CS) and B, dermatan sulfate (DS) were quantified by agarose gel electrophoresis. C, ELISA-like assay was used to
determine the amount of hyaluronic acid (HA). The number of samples (N = 10 and N = 7), for control and Peyronie’s group, respectively. Box-plot represents the median value
of each group (central line) and ranges. The percentiles are shown in the attached table. There was a significant difference comparing control group (unaffected individuals)
and Peyronie’s (patients affected by Peyronie’s disease) for CS, while no difference was observed for DS and HA. Mann-Whitney test was used to obtain P values.
Fig. 7. Expression of hyaluronic acid synthases (HAS1, HAS2 and HAS3) and hyaluronidases (HYAL1 and HYAL 2). The expression of mRNA from hyaluronic acid synthases and
hyaluronidases were obtained by quantitative RT-PCR. The number of samples used was described in methods (N = 10 and N = 7), for control and Peyronie’s group,
respectively. The normalization of the expression of the target genes was determined using the geometric mean of the two endogenous genes, glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) and b-actin, and the values of expression were corrected using 2DCt. The values are expressed as mean and standard deviation using nonparametric
unpaired test.
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sues affected by Peyronie’s there was a remodeling process of the
extracellular matrix, and such events are not associated with met-
alloprotease (MMP2 and MMP9) expression.
Syndecan-1 is themost ubiquitous heparan sulfate proteoglycan
(HSPG) present in the cytoplasmic membranes. The major functionof HSPG is modulating the action of growth factors, and it is also
involved in interactions between cell-cell and cell-extracellular
matrix [14,15]. Some authors have demonstrated HSPG shedding
with enhanced activity of heparanase-1 [16,17]. However, the pre-
sent data showed that the expression of syndecan-1was not altered
in the tissues affected by Peyronie’s disease.
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fate and chondroitin sulfate can modulate TGF-b positively, acting
as a co-receptor, and enhance the response of this factor [5,18,19].
Consequently, the increase of chondroitin sulfate in Peyronie’s
samples reinforces the hypothesis that such compound is altered
in albuginea tissues from patients with Peyronie’s disease com-
pared to non-affected tissues. It is not possible to determine if
chondroitin sulfate is involved with the development of the Pey-
ronie’s disease or it is a result of the changes that lead to the plaque
formation. Although we do not have experimental evidence, we
can hypothesize that higher levels of chondroitin sulfate could
intensify the effect of TGF-b.
It is well known that high molecular weight HA is involved in
cell signaling pathways for adhesion, migration and cell prolifera-
tion as well as activation of tyrosine kinases. Nevertheless, low
molecular weight HA seems to be involved in the inflammation
process, inducing the production of cytokines and contributing to
macrophage activation as well as angiogenesis [20–22]. Further-
more, high molecular weight HA was synthesized by HAS1 and
HAS2, while HAS3 is involved in the synthesis of low molecular
weight HA, and HA was degraded essentially by Hyl1 and Hyal2
[23,24]. No alterations observed in the expression of the enzymes
involved in the synthesis and degradation of HA validate the result,
which showed no difference in the quantification of this gly-
cosaminoglycan in both Peyronie’s and control tissues.
These combined data suggest that hyaluronic acid is possibly
not involved in extracellular matrix alterations in the development
of Peyronie’s disease and also elucidate that HAS3 might not be
expressed in the albuginea tissue.
A recent article in the literature found that intralesional injec-
tion of hyaluronic acid, in the early stage of the Peyronie’s disease,
improved plaque size, penile curvature and sexual satisfaction
[25]. Moreover, another study using hyaluronic acid as treatment
after laparoscopic pelvic surgery showed a significant reduction
in bowel adhesion to abdominal wall [26].
Although the amount of hyaluronic acid was not altered in Pey-
ronie’s disease, the treatment with exogenous molecule, especially
high molecular weight hyaluronic acid (HMW-HA), might be effec-
tive in decreasing scar formation (tissue regeneration) and block-
ing the side effects of inflammation as previously described as a
biological function of HMW-HA [20].Conclusions
Increased expression of heparanases as well as enhanced
amounts of CS suggest that such molecules are involved in the
molecular alterations of Peyronie’s disease. Higher levels of CS
may act as a co-receptor, thus enhancing the response of TGF-b
mediated by proteoglycans such as decorin and biglycan.
Heparanase-1 may be related to an intensification of the inflamma-
tory process, essential for plaque formation, while heparanase-2
could be important in modulating the activity of heparanase-1,
since both heparanases have affinity for heparan sulfate. These
novel data demonstrated extracellular matrix changes in Pey-
ronie’s disease. Such findings may contribute to the elucidation
of key molecules that are altered in the albuginea tissue of patients
with Peyronie’s disease and may be useful as target molecules for
future therapies.Conflict of interest
The authors have declared no conflict of interest.References
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